MabVax Therapeutics, Inc.

Industry

  • Biotechnology
    • Large Molecule
      • Antibodies
  • Miscellaneous
  • Pharmaceuticals
    • Vaccines
See more in Biomedtracker

Latest on MabVax Therapeutics, Inc.

Scrip

Deal Watch: Gilead Moves Into Kidney Disease Via Goldfinch Collaboration

 
• By Joseph Haas and John Davis

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Gilead Pays Goldfinch $55m U

Scrip

Deal Watch: Sanofi Retains Options To Two Bispecifics While Exiting Antibody Pact With Regeneron

 
• By Joseph Haas and Emily Hayes

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Sanofi, Regeneron Unwind Lon

Scrip

Neuroblastoma Genomic Discovery Gateway To Potential Therapies

 
• By Lubna Ahmed

Scientists at NEO New Oncology AG and the University of Cologne have identified previously unknown genomic alterations in neuroblastoma which may help improve tumor diagnostics and potentially leading

Pink Sheet

Deal Watch: Seattle Genetics And Genmab Partner Again On Anti-Cancer ADC

 
• By John Davis, Sten Stovall, Lisa LaMotta, and Jessica Merrill

“The Pink Sheet” regularly presents commentary and perspective on key business deals. Here is a summary of the most noteworthy transactions that occurred between Sept. 6 and Sept. 12. Seattle Genetic